www.fdanews.com/articles/152468-fda-accepts-astellas-supplemental-new-drug-application-for-tarceva

FDA Accepts Astellas Supplemental New Drug Application for Tarceva

January 17, 2013

The USFDA has accepted for filing Astellas Pharma’s supplemental new drug application (sNDA) for Tarceva (erlotinib) tablets for a genetically distinct form of advanced lung cancer.
Pharmaceutical Business Review